Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions.

Meisong Ding, William Zollinger, Robert Ebeling, David Heard, Ryan Posey

Abstract read

In one paragraph

Article in Journal of applied clinical medical physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Evaluation of tumor response after stereotactic body radiation therapy for lung cancer: Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography.Journal of clinical and translational research · 2020
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meisong DingDepartment of Radiation Oncology, Tulane University Medical Center, New Orleans, LA, USA.

William ZollingerNortheast Louisiana Cancer Center, Monroe, LA, USA.

Robert EbelingNortheast Louisiana Cancer Center, Monroe, LA, USA.

David HeardNortheast Louisiana Cancer Center, Monroe, LA, USA.

Ryan PoseyNortheast Louisiana Cancer Center, Monroe, LA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo retrospectively investigate tumor responses of lung SBRT patients for different prescriptions. To analyze the relation between optimal biologically equivalent dose (BED) and tumor responses. METHODS AND MATERIALS: Tumor responses after lung SBRT were compared by examining 48 treatments used four prescriptions. This study used simplified tumor response criteria: (a) Complete Response (CR) - post max SUV (SUV

resultsFor the prescriptions (9 Gy × 5, 10 Gy × 5, 11 Gy × 5, and 12 Gy × 4) historically recommended by RTOG, we observed that higher BED

conclusionWe demonstrated post max SUV read from PET/CT could efficiently and accurately assess tumor response after lung SBRT. Although SBRT with prescriptions resulting in a BED

Indexed as

Carcinoma, Non-Small-Cell LungFluorodeoxyglucose F18Follow-Up StudiesHumansImage Processing, Computer-AssistedLung NeoplasmsPositron-Emission TomographyPrognosisRadiometryRadiopharmaceuticalsRadiosurgeryRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedRetrospective StudiesFluorodeoxyglucose F18Radiopharmaceuticalscomputed tomography (CT)maximum standardized uptake value (SUV)positron emission tomography (PET)stereotactic body radiotherapy (SBRT)tumor responses

Identifiers

PMID30216639

DOI10.1002/acm2.12453

PMCPMC6236840

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.